Evolving Treatments for Chronic Kidney Disease and Complications

Release Date: June 24, 2021
Expiration Date: December 31, 2021

Launch Presentation Download Handout

Diabetes is the leading cause of end-stage renal disease (ESRD). Cardiovascular (CV) death is more likely than progression to end-stage renal disease in patients with chronic kidney disease (CKD), and protecting against renal decline decreases CV risk. In this activity, the faculty reviews three complications associated with renal dysfunction (heart failure, anemia, and hyperkalemia) and describes current and evolving treatment options for chronic kidney disease and these complications.  

Learning Objectives

  • Describe the disease burden of chronic kidney disease (CKD) and its impact on other comorbidities.
  • Discuss three complications associated with diabetes and/or kidney dysfunction: heart failure, anemia, and hyperkalemia.
  • Summarize current and evolving treatment options for patients with CKD.
  • Apply the guideline recommendations for routine screening for CKD in patients with cardiorenal-metabolic disease.

This webinar is not accredited for continuing education.


Kelley Doherty Sanzen, Pharm.D., CDOE, PAHM
Clinical Pharmacist Specialist
Brown Medicine Division of Kidney Disease and Hypertension
Providence, Rhode Island


In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.

In this activity, no persons associated with this activity have disclosed any relevant financial relationships.

Target Audience

This activity was planned to meet the educational needs of pharmacists and pharmacist decision makers who care for or have an interest in the care of patients with type 2 diabetes.